CYTK - Potential Takeover In Works for Cardiovascular Treatment Focused Cytokinetics | Benzinga
Cytokinetics Inc (NASDAQ: CYTK), a late-stage biotech company focused on cardiovascular treatments, is reportedly exploring potential takeover options as it has garnered interest from at least one major pharmaceutical company in recent months.
While the company has not disclosed any specifics, it is currently assessing its next course of action.
Citing sources, the Bloomberg report suggests that potential suitors may wait until Cytokinetics releases data from an upcoming Phase 3 ...